Rosen Law Firm Investigates Potential ADMA Biologics Securities Fraud

Firm Encourages ADMA Investors to Contact Them About Potential Compensation

Apr. 18, 2026 at 9:20pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of financial documents, a calculator, and a gavel floating on a clean, monochromatic grey background, conceptually representing the abstract legal and financial issues surrounding the ADMA Biologics investigation.A legal investigation into alleged corporate misconduct could have significant financial implications for ADMA Biologics and its investors.NYC Today

The Rosen Law Firm, a global investor rights law firm, has announced an investigation into potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). The investigation comes after allegations that ADMA Biologics may have issued materially misleading business information to the investing public.

Why it matters

This investigation could lead to a class action lawsuit and potential compensation for ADMA Biologics investors who suffered losses. The Rosen Law Firm has a track record of success in securities class actions and shareholder litigation, having recovered hundreds of millions of dollars for investors in the past.

The details

On March 24, 2026, Investing.com published an article stating that ADMA Biologics shares fell 16.6% after short seller Culper Research released a report alleging the company engaged in 'channel stuffing to inflate revenue growth.' The Rosen Law Firm is now investigating these allegations and preparing a potential class action lawsuit on behalf of ADMA investors.

  • On March 24, 2026, ADMA Biologics stock fell 16.6% on the short seller allegations.
  • The Rosen Law Firm announced its investigation on April 18, 2026.

The players

The Rosen Law Firm, P.A.

A global investor rights law firm that specializes in securities class actions and shareholder derivative litigation. The firm has recovered hundreds of millions of dollars for investors and has been ranked among the top plaintiffs' firms in the country.

Culper Research

A short-selling research firm that released a report alleging ADMA Biologics engaged in 'channel stuffing to inflate revenue growth.'

ADMA Biologics, Inc.

A biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel.”

— Laurence Rosen, Founding Partner, The Rosen Law Firm

What’s next

The Rosen Law Firm is preparing a class action lawsuit seeking recovery of investor losses related to the ADMA Biologics allegations. Investors are encouraged to contact the firm to join the prospective class action.

The takeaway

This investigation highlights the importance of thorough due diligence and the need for investors to be cautious of potential corporate misconduct. The Rosen Law Firm's track record suggests they may be well-positioned to represent ADMA investors in any forthcoming legal action.